NeuroVive, Sanofi enter commercialization deal for Ciclomulsion in South Korea
As part of the deal, NeuroVive Asia will get an upfront payment, a conditional milestone payment and royalty on potential future sales in South Korea. The deal will
The US Food and Drug Administration (FDA) has expanded the approved indication for Bristol Myers Squibb’s (BMS) Camzyos (mavacamten) to treat symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adults and paediatric patients weighing at least 30kg (66lb).
Unituxin, a monoclonal antibody, is intended for use in children who have responded to an induction treatment with chemotherapy, followed by myeloablative therapy and autologous stem-cell transplantation. Neuroblastoma
Tanner Pharma Group includes three complementary divisions Tanner Clinical Trial Sourcing (TannerCTS), Tanner Global Access Programs (TannerGAP) and Tanner Licensing, Acquisition and Commercialisation (TannerLAC). The new firm’s complementary